Lau on Liraglutide: Is It Safe? AACE Video
NASHVILLE (MedPage Today) -- Exclusive AACE Video Conference Reporter coverage, with Hallway Takes from David C.W. Lau, PhD, on Liraglutide Safety; Shashank R. Joshi, MD, on the Saragliptin Trial; and Carolina Solis-Herrera, MD, on the Dapagliflozin Trial. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 18, 2015 Category: Cardiology Source Type: news
Three Diabetes Drugs Linked to Ketoacidosis, FDA Warns
(MedPage Today) -- FDA targets SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 16, 2015 Category: Cardiology Source Type: news
Dapagliflozin in Patients With Type 2 Diabetes MellitusDapagliflozin in Patients With Type 2 Diabetes Mellitus
Where does this SGLT2 inhibitor fit in type 2 diabetes therapy? Therapeutic Advances in Endocrinology and Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Sodium-Glucose Cotransporter 2 Inhibitors for T2DMSodium-Glucose Cotransporter 2 Inhibitors for T2DM
Learn about the new sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin in this overview, including their benefits, adverse effects, and potential place in therapy. Southern Medical Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Dapagliflozin Efficacy and Safety: A Perspective ReviewDapagliflozin Efficacy and Safety: A Perspective Review
How does short-term efficacy of this SGLT-2 inhibitor compare with other antidiabetic drugs? Therapeutic Advances in Drug Safety (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
dapagliflozin, Farxiga
Title: dapagliflozin, FarxigaCategory: MedicationsCreated: 12/1/2014 12:00:00 AMLast Editorial Review: 12/1/2014 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 1, 2014 Category: Endocrinology Source Type: news
dapagliflozin, Farxiga
Title: dapagliflozin, FarxigaCategory: MedicationsCreated: 12/1/2014 12:00:00 AMLast Editorial Review: 12/1/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 1, 2014 Category: Drugs & Pharmacology Source Type: news
Top medicine articles for November 2014
A collection of some interesting medical articles published recently:'To Burn Off Calories in This Soda, Walk 5 Miles' - new label http://buff.ly/1vzbCKHTwo new medications for IPF: Pirfenidone (Esbriet) affects scarring, Nintedanib (Ofev) is a kinase inhibitor http://buff.ly/1psam6m80% of people have at least 1 distressing symptom in a given month, yet fewer than 1 in 4 persons sees a doctor. At least one third of common symptoms do not have a clear-cut, disease-based explanation. History and physical examination alone contribute 73% to 94% of the diagnostic information. The patient's history alone yields 75% of the diagn...
Source: Clinical Cases and Images - November 17, 2014 Category: Journals (General) Tags: Health News of the Day Source Type: news
Xigduo XR (Dapagliflozin and Metformin HCl Extended-release Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 7, 2014 Category: Drugs & Pharmacology Source Type: news
New Diabetes Combo Approved
(MedPage Today) -- Dapagliflozin plus metformin -- one tablet, once daily -- given FDA nod. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 3, 2014 Category: Cardiology Source Type: news
FDA OKs Xigduo XR, a New Dapagliflozin-Metformin ComboFDA OKs Xigduo XR, a New Dapagliflozin-Metformin Combo
Xigduo XR is the first diabetes drug in the United States to combine a sodium glucose cotransporter-2 inhibitor with metformin hydrochloride extended-release. FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 30, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
First U.S. approval for once-daily tablet combining SGLT2 inhibitor and metformin HCl extended-release
WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--AstraZeneca (AZN) today announced that the U.S. Food and Drug Administration has approved on... Biopharmaceuticals, Endocrinology, FDAAstraZeneca, XIGDUO XR, dapagliflozin, metformin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2014 Category: Pharmaceuticals Source Type: news
Pilot Study Explores Dapagliflozin Use in Type 1 DiabetesPilot Study Explores Dapagliflozin Use in Type 1 Diabetes
Already approved for use in type 2 diabetes, the SGLT2 inhibitor dapagliflozin is tested in a pilot trial in patients with type 1 diabetes along with insulin therapy. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 8, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
AstraZeneca’s Forxiga receives positive advice from Scottish Medicines Consortium
AstraZeneca announced that the Scottish Medicines Consortium (SMC) has issued positive advice for use of its Forxiga, a selective and reversible inhibitor of sodium-glucose co-transporter-2, as part of a triple therapy regimen for type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 7, 2014 Category: Pharmaceuticals Source Type: news
Added benefit of the fixed combination of dapagliflozin, metformin is not proven, study finds
As was the case in dapagliflozin monotherapy, a drug manufacturer also presented no suitable data for the therapeutic indication in its dossier on the fixed combination with metformin. Dapagliflozin is approved both alone and in combination with other blood-glucose lowering drugs, including insulin. The fixed combination with metformin is an option for patients who are already taking dapagliflozin and metformin as separate tablets or for patients or who do not benefit sufficiently from the commonly used drug metformin. It can also be used together with other blood-glucose lowering drugs, including insulin, if metformin and...
Source: ScienceDaily Headlines - May 15, 2014 Category: Science Source Type: news
